Phase 3
N=100
Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019
HIV Infections
Bottom Line
View on ClinicalTrials.gov: NCT03016533 ↗Enrolled (actual)
100
Serious AEs
8.0%
Results posted
Feb 2026
Primary outcome: Primary: Number of Participants With Continued Access to Age Appropriate Formulation of Dolutegravir — 53; 29 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- Dolutegravir film-coated tablets (Drug); Dolutegravir film-coated dispersible tablets (Drug); ABC/DTG/3TC immediate release tablets (Drug); ABC/DTG/3TC film-coated dispersible tablets (Drug)
- Age
- Pediatric, Adult
- Sex
- All
- Sponsor
- ViiV Healthcare
- Primary completion
- Dec 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Continued Access to Age Appropriate Formulation of Dolutegravir |
53; 29 | — |
| SECONDARY Number of Participants With Any Serious Adverse Events (SAEs) |
5; 3 | — |
| SECONDARY Number of Participants With SAEs Leading to Discontinuation of Study Treatment |
0; 0 | — |
| SECONDARY Number of Participants With Any Clinical or Laboratory Adverse Events (AEs) Leading to Discontinuation of Study Treatment |
0; 0 | — |
Summary
Dolutegravir is a potent integrase strand transfer inhibitor. Abacavir/dolutegravir/lamivudine (ABC/DTG/3TC) is a fixed dose combination regimen containing two nucleoside reverse transcriptase inhibitors and dolutegravir. This is a phase 3b, non-randomized, open-label, multi-center, two treatment rollover study. The primary objective of this pediatric interventional study is to provide continued access to age appropriate formulations of investigational product (dolutegravir), either as Tivicay or as part of fixed dose combination ABC/DTG/3TC, for eligible participants who previously participated in parent studies P1093 (NCT01302847) or P2019 (NCT03760458) and who cannot locally access age appropriate formulations of dolutegravir or ABC/DTG/3TC in the public sector. The P1093 study was designed to evaluate the pharmacokinetics (PK), safety, tolerability and antiviral activity of dolutegravir in combination with optimized background regimens in human immunodeficiency virus type 1 (HIV-1) experienced adolescents and children as well as treatment naïve infants and toddlers. The P2019 study was designed to evaluate PK, safety, tolerability and antiviral activity of ABC/DTG/3TC dispersible and immediate release tablets in HIV-1-infected children. Participants who have tolerated investigational product in the parent studies without any significant toxicity or signs of virologic failure leading to the permanent discontinuation of investigational product and withdrawal from the parent study will be considered for this open label continued access study. Participants will receive their age/weight appropriate dose of investigational product as defined in the parent study. The duration of participation in the study will extend until age appropriate formulations of Tivicay or ABC/DTG/3TC receive local (by country) regulatory approval and are available in those countries from another source (e.g. government programs, aid programs, assistance programs, etc.) or the participant is no longer deriving benefit from treatment or meets a protocol defined reason for discontinuation. Participants will be enrolled after all screening procedures have been completed. In most cases, the Screening visit will overlap with the participants penultimate visit on the parent study (at Week 180 of P1093, or Week 36 of the P2019 study). Participants who meet all entry criteria may enroll and will be seen in the clinic every 12 weeks for a safety evaluation and to receive investigational product. It is estimated that no more than 300 participants will be enrolled in this study. Tivicay is a registered trademark of ViiV Healthcare.
Eligibility Criteria
Inclusion Criteria
- Participant must have completed participation in one of the following parent studies, for the duration noted, with continued benefit from investigational product:
- P1093 parent study through at least Week 180;
- P2019 parent study through at least Week 48.
- Participant with evidence of Virological Failure in either parent study must have eligibility for this rollover study discussed and agreed with the ViiV Healthcare Medical Monitor.
- Virological control:
- Participants in parent study P1093 must have virological control defined as HIV-1 ribonucleic acid (RNA) =18 years of age is able and willing to provide signed informed consent.
Exclusion Criteria
- Confirmed virologic failure with evidence of resistance to:
- DTG in the P1093 parent study, or
- ABC, DTG or 3TC (with the exception of M184V) in the P2019 parent study
- Presence of any active AIDS defining opportunistic infection.
- Known >=grade 3 laboratory toxicities prior to study entry (e.g. neutrophil count, hemoglobin, platelets, aspartate aminotransferase [AST], alanine aminotransferase [ALT], lipase, serum creatinine and total bilirubin) would be considered exclusionary if identified at or after the penultimate parent study visit, prior to enrollment in the study... Repeat testing is allowed for eligibility determination.
- Previous permanent discontinuation from investigational product in the parent study due to toxicity, intolerance or pregnancy.
- Known ALT >=5 times the upper limit of normal (ULN), or ALT >=3 times ULN and bilirubin >=1.5 times ULN (with >35 percent [%] direct bilirubin) would be considered exclusionary if identified at or after the penultimate parent study visit, prior to enrolment in the study.. Participants with moderate to severe hepatic impairment (Class B or greater) as determined by Child-Pugh classification should be excluded.
- Participants positive for hepatitis B virus at any time prior to entry (hepatitis B virus surface antigen positive).
- Females who are pregnant or plan to become pregnant or breastfeed during the study.
- Participant is currently participating in or has participated in a study with a compound or device that is not commercially available within 30 days of signing informed consent, unless permission from the sponsor's medical monitor is granted.
- Presence of any history of allergy/sensitivity to any of the study drugs.
- Participants transitioning from the P2019 study (taking ABC/DTG/3TC) have evidence of being Human Leukocyte Antigen-B*5701- positive based on documented testing at any time prior to entry.
- Use of any disallowed medications at time of Screening.
- Anticipated need for Hepatitis C virus therapy with interferon or any drugs that have potential for adverse drug: drug interactions with study treatment throughout the entire study period.
- Participant is unlikely to adhere to the study procedures, keep appointments, or is planning to relocate during the study.
- Clinical or symptomatic evidence of pancreatitis, as determined by the clinician.
- Any condition (including but not limited to alcohol and drug use) that would, in the opinion of the site investigator, place the participant at an unacceptable risk of injury or render the participant unable to meet the requirements of the protocol.
Data sourced from ClinicalTrials.gov (NCT03016533). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.